Investors

 

Synthase is presently completing an expanded round from existing shareholders. In September 2020 it will launch a new capital round for approx. NZ $2-3million to fund completion of cattle work prior to sales, entry into the global pig fertility market and entry into two human applications (yet to be finalised).

Our shareholding base includes the Board and management; private individuals; three of New Zealand’s principal angel investment entities - Enterprise Angels, Ice Angels and Marlborough Angels; and the New Zealand Government through its specialist, hi-tech investment fund, NZ Growth Capital Partners. We have also continued to receive a significant backing from the NZ Government’s hi-tech support agency, Callaghan Innovation. Interested investment parties may contact Dr Andrew West (Managing Director – a.west@synthasebiotech.com ) or Mark Backhaus (Chairman – m.backhaus@synthasebiotech.com ).